BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model - PubMed (original) (raw)
doi: 10.1016/j.ymthe.2003.10.012.
Kiminori Nakamura, Takashi Tamiya, Yutaka Kawano, Masayoshi Kobune, Sachie Hirai, Hiroaki Uchida, Katsunori Sasaki, Yoshinori Ito, Kazunori Kato, Osamu Honmou, Kiyohiro Houkin, Isao Date, Hirofumi Hamada
Affiliations
- PMID: 14759803
- DOI: 10.1016/j.ymthe.2003.10.012
Free article
BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model
Kazuhiko Kurozumi et al. Mol Ther. 2004 Feb.
Free article
Erratum in
- Mol Ther. 2004 May;9(5):766
Abstract
Examination of the clinical therapeutic efficacy of using bone marrow stromal cells, including mesenchymal stem cells (MSC), has recently been the focus of much investigation. MSC were reported to ameliorate functional deficits after stroke in rats, with some of this improvement possibly resulting from the action of cytokines secreted by these cells. To enhance such cytokine effects, we transfected telomerized human MSC with the BDNF gene using a fiber-mutant F/RGD adenovirus vector and investigated whether these cells contributed to improved functional recovery in a rat transient middle cerebral artery occlusion (MCAO) model. BDNF production by MSC-BDNF cells was 23-fold greater than that seen in uninfected MSC. Rats that received MSC-BDNF showed significantly more functional recovery than did control rats following MCAO. Specifically, MRI analysis revealed that the rats in the MSC-BDNF group exhibited more significant recovery from ischemia after 7 and 14 days. The number of TUNEL-positive cells in the ischemic boundary zone was significantly smaller in animals treated with MSC-BDNF compared to animals in the control group. These data suggest that MSC transfected with the BDNF gene may be useful in the treatment of cerebral ischemia and may represent a new strategy for the treatment of stroke.
Similar articles
- [Therapeutic efficacy of lentiviral vector mediated BDNF gene-modified MSCs in cerebral infarction].
Huang D, Zhang Z, Chen B, Wu X, Wang N, Zhang Y. Huang D, et al. Sheng Wu Gong Cheng Xue Bao. 2008 Jul;24(7):1174-9. Sheng Wu Gong Cheng Xue Bao. 2008. PMID: 18837391 Chinese. - Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model.
Kurozumi K, Nakamura K, Tamiya T, Kawano Y, Ishii K, Kobune M, Hirai S, Uchida H, Sasaki K, Ito Y, Kato K, Honmou O, Houkin K, Date I, Hamada H. Kurozumi K, et al. Mol Ther. 2005 Jan;11(1):96-104. doi: 10.1016/j.ymthe.2004.09.020. Mol Ther. 2005. PMID: 15585410 - Comparsion between Intravenous Delivered Human Fetal Bone Marrow Mesenchymal Stromal Cells and Mononuclear Cells in the Treatment of Rat Cerebral Infarct.
Huang AH, Zhang PP, Zhang B, Ma BQ, Guan YQ, Zhou YD. Huang AH, et al. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016 Oct 10;38(5):497-506. doi: 10.3881/j.issn.1000-503X.2016.05.002. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016. PMID: 27825404 - Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy.
Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, Honmou O, Houkin K, Matsunaga T, Niitsu Y. Hamada H, et al. Cancer Sci. 2005 Mar;96(3):149-56. doi: 10.1111/j.1349-7006.2005.00032.x. Cancer Sci. 2005. PMID: 15771617 Free PMC article. Review. - Neuroprotective Effects of Conditioned Medium of Mesenchymal Stem Cells (MSC-CM) as a Therapy for Ischemic Stroke Recovery: A Systematic Review.
Behzadifard M, Aboutaleb N, Dolatshahi M, Khorramizadeh M, Mirshekari Jahangiri H, Kord Z, Nazarinia D. Behzadifard M, et al. Neurochem Res. 2023 May;48(5):1280-1292. doi: 10.1007/s11064-022-03848-x. Epub 2022 Dec 30. Neurochem Res. 2023. PMID: 36581731 Review.
Cited by
- Neurotrophic factor-based pharmacological approaches in neurological disorders.
Alfonsetti M, d'Angelo M, Castelli V. Alfonsetti M, et al. Neural Regen Res. 2023 Jun;18(6):1220-1228. doi: 10.4103/1673-5374.358619. Neural Regen Res. 2023. PMID: 36453397 Free PMC article. Review. - Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.
Hall B, Dembinski J, Sasser AK, Studeny M, Andreeff M, Marini F. Hall B, et al. Int J Hematol. 2007 Jul;86(1):8-16. doi: 10.1532/IJH97.06230. Int J Hematol. 2007. PMID: 17675260 Review. - Neuroinflammation in Cerebral Ischemia and Ischemia/Reperfusion Injuries: From Pathophysiology to Therapeutic Strategies.
Jurcau A, Simion A. Jurcau A, et al. Int J Mol Sci. 2021 Dec 21;23(1):14. doi: 10.3390/ijms23010014. Int J Mol Sci. 2021. PMID: 35008440 Free PMC article. Review. - Transplantation of IL-1β siRNA-modified bone marrow mesenchymal stem cells ameliorates type II collagen-induced rheumatoid arthritis in rats.
Pan S, Dong X, Wang Y, Zhou T, Liu Y, Zhou A, Xing H. Pan S, et al. Exp Ther Med. 2022 Feb;23(2):139. doi: 10.3892/etm.2021.11062. Epub 2021 Dec 14. Exp Ther Med. 2022. PMID: 35069820 Free PMC article. - Hypoxia inducible factor 1α promotes survival of mesenchymal stem cells under hypoxia.
Lv B, Li F, Fang J, Xu L, Sun C, Han J, Hua T, Zhang Z, Feng Z, Jiang X. Lv B, et al. Am J Transl Res. 2017 Mar 15;9(3):1521-1529. eCollection 2017. Am J Transl Res. 2017. PMID: 28386377 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials